Covid-19 vaccination- A watershed for India’s public health | The Financial Express

Covid-19 vaccination- A watershed for India’s public health

Seizing lessons from the pandemic for a better future is the smartest choice we can make

Covid-19 vaccination- A watershed for India’s public health
The development of safe, effective vaccines for a novel virus like SarsCoV2 in less than a year will go down as one of the most impressive feats in the history of modern science. (Photo: Ministry of Health Twitter)

By Adar Poonawalla

In the ‘far from normal’ last two and half years, where humanity came the closest to living in a ‘science fiction’, India and Indians under the untiring leadership of PM Narendra Modi can collectively claim that we learnt crucial, once-in-a lifetime lessons during the Covid-19 crisis. We demonstrated resilience, determination and strength that has earned respect the world over, and that is an immense accomplishment in itself.

Such a claim can be made for the vaccine space in India, too.Be it the vaccine manufacturing prowess of India, innovations/trials in R&D, unleashing the potential of public-private partnerships, digitalisation of vaccination drive, how government departments came together on a mission mode; under the leadership of PM Modi, or the efforts taken to communicate and convince a billion people to take life-saving jabs, we can claim to have put together lessons of decades into two years, to succeed on many fronts. That’s no small achievement, particularly amid rapidly-shifting realities, and real-time evolving science, against the backdrop of social discord and vaccine hesitancy in so many countries.

The development of safe, effective vaccines for a novel virus like SarsCoV2 in less than a year will go down as one of the most impressive feats in the history of modern science. And the role of India’s vaccine ecosystem will get etched in that history. Despite myriad local challenges such as accidents, and global ones such as acute shortage of raw-materials Serum Institute of India (SII), the world’s largest vaccine manufacturer by doses, and other Indian vaccine-makers churned out well over 2 billion doses—sufficient to cover almost a third of humanity on the planet if one dose offered immunity to an individual. That scale of manufacturing is a mere indicator of the potential India has to offer to the world as vaccines grow more high-tech and offer life-course protection against several other diseases across ages.

The country also excelled in providing health tech solutions best showcased by CoWIN, the digital backbone of the vaccination drive. The speed with which India adapted e-Vin, its smart vaccine supply chain management system used in universal vaccination program meant for children and expecting women, into CoWIN has been exemplary. India had started issuing digital vaccine certificates right from the start, at a time when many developed countries were struggling to digitise vaccine certificates and were issuing it manually. CoWIN remains that valuable platform that can prove handy if other universal or age-specific vaccines are to be administered, either responding to an emergency or in a well-planned programme. It is an asset that can also be adapted for other public health programmes in various ways.

Also Read: Incentivising RPs

Three areas where the country took a leap in attempting novel experiments and reaped rich learnings are vaccine research and development, the drug regulatory system, and the deep engagement of the government—across departments—with private players to shape the Covid-19 response. First, fully aware of how uncertain the path of vaccine discovery could turn out to be, particularly during a raging pandemic, the government chalked out a well thought out strategy.

That made sense as one didn’t know at the time which one would click, and even if multiple vaccine candidates succeeded, which one would emerge the safest, most efficacious and most convenient to use. In vaccine-making, a science so complex, the first is not necessarily the best. Betting on a pipeline that was numerically rich, and technology-wise diverse meant that the scientific community and innovation ecosystem packed a decade of learning into a year. It also showed us what was possible in vaccine development if companies, policymakers, and scientists came together.

Our drug-regulatory system, traditionally badgered as slow-moving, learnt to put in place accelerated pathways to approve vaccines, like many global regulators in mature markets. Keeping patient safety as the top priority, these lessons of agility and efficiency would seep into the workflow of the regulatory system, if the war against other diseases, equally or more dreaded than Covid-19, have to be waged effectively and forcefully.

What also helped in shaping the pandemic response was the way the government turned into one ‘whole’. Under the guidance of PM Modi, a number of inter-disciplinarian, inter-departmental empowered groups broke the culture of working in specialised silos and practiced what is now hailed as the ‘whole of government’ approach, taking swift decisions. Industry too was involved as an important stakeholder in many areas. All stakeholders including media, local influencers, civil societies and international as well as national partners played supportive roles. Continuing this approach well into the future has the potential to strengthen our country’s response to other public health challenges.

Finally, one of the most fundamental but valuable lessons we have learnt is to communicate transparently and engage effectively with the community in public health contexts and exhort them to place their faith in science in a language they understand best. From cutting-edge technologies like drones to deeply traditional auspicious symbols such as turmeric, from 24×7 public health and risk communication disseminated across the county, coupled with a range of innovative communication strategies were employed to invite people for vaccination or reach the last mile with vaccines.

At a time when many developed countries struggled with the anti-vaxxers movement, Indians showed through their overwhelming participation in the vaccination drive that it’s a country where scientific temper trumps hesitancy hands down. Despite being the second-most populous country, 96.7% of the eligible population have been vaccinated with the first dose, 89.2% have taken both doses, and over 18.7 crore precaution doses have been administered. It is a clear testament to Covid-19 vaccination’s grand success. Special campaigns are being conducted across the country to encourage eligible beneficiaries to take up their due doses.

In 2021 alone, Covid-19 vaccination programmes averted nearly 20 million deaths globally, according to an estimate cited in Human Development Report 2022. Despite all the challenges, India, under the leadership of PM Modi, has truly turned the response to covidpandemic into a jan andolan (people’s movement) through the ‘whole of government’ approach, with participation by all stakeholders.

The author is CEO, Serum Institute of India

Get live Share Market updates and latest India News and business news on Financial Express. Download Financial Express App for latest business news.